Abstract
Exported across the world might create a serious controversy. Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV2) infection into the host undergoes a huge number of complex replicative
machineries which remains unclear. Understanding the mechanism (s) of replication and mode of
infection of SARS-CoV2 to human cells will help us in the development of novel vaccines or drugs for
the eradication and prevention of the disease. This review compiles the knowledge of SARS-CoV2 replicative
machinery, mode of infection to the human cells and the development of drugs and vaccines
which are currently under clinical trials.
Keywords:
Coronavirus, COVID-19, SARS, ACE-2, spike protein, vaccines, infection.
[6]
Yan R, Zhang Y, Guo Y, Xia L, Zhou Q. Structural basis for the recognition of the 2019-nCoV by human ACE2. bioRxiv 2020.
[10]
Chen T, Rui J, Wang Q, Zhao Z, Cui J-A, Yin L. A mathematical model for simulating the transmission of Wuhan novel Coronavirus. bioRxiv 2020.
[12]
Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected
With 2019 Novel Coronavirus Case Med Res 2020.
[44]
Bos ECW, Luytjes W, Van Der Meulen H, Koerten HK, Spaan WJM. The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus. Virology 1996; 218: 52-60.
[55]
Leronlimab (PRO 140) Combined With Carboplatin in Patients
With CCR5+ mTNBC Case Med Res 2000.
[57]
NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins. 2020.
[58]
Clover Successfully Produced 2019-nCoV Subunit Vaccine
Candidate and Detected Cross- Reacting Antibodies from Sera of
Multiple Infected Patients 2020.